Abstract
Background/Aims. This study evaluates changes of flow and structure of diabetic retinal neovascularization (NV) treated with intravitreal antivascular endothelial growth factor (VEGF) agents using optical coherence tomography angiography (OCTA). With OCTA, retinal blood vessels are visualized at high resolution to separately look at flow and structure information without the need for dye injection. We introduce a new measurement method including and combining information of flow and structure. Methods. Retrospective observational case series. Patients with proliferative diabetic retinopathy (PDR) were treated with intravitreal antiVEGF injections. Retinal NV were repeatedly imaged using swept-source OCTA (Zeiss PlexElite 9000) at baseline, after initial treatment block with 3-4 monthly injections, and during a follow-up period of up to 51 weeks. Change of size and flow density of the structural and angio area of NV was assessed. Results. Nine NV in eight eyes of five patients were analyzed with a median follow-up time of 45 weeks. After the initial treatment block, en face structural area regressed, 18.7% ± 39.0% (95% CI 44.2–6.8%, p=0.26), and en face angio area regressed, 51.9% ± 29.5% (95% CI 32.6 to 71.2%, p=0.007). Flow density within the en face structural area decreased by 33% ± 19.2% (95% CI 20.5–45.5%, p=0.0077). Flow density within the en face angio area decreased by mean 17.9% ± 25.2% (95% CI 1.4–34.4%, p=0.066). In two fellow eyes, NV recurrence could be observed before the onset of vitreous bleeding in one. Conclusion. Our study introduces a new quantitative measurement for NV in PDR, combining structure and flow measurement. The structure area remained after treatment, while its flow density and angio area regressed. We propose this measurement method as a more physiological and possibly more comparable metrics.
Highlights
Diabetic retinopathy (DR) is a leading cause of vision loss and blindness worldwide and presumably on the rise with expected demographics [1, 2]
As new diagnostic and therapeutic possibilities emerge for proliferative diabetic retinopathy (PDR), there is the potential for gaining new insights into the pathophysiology of the development of NVs and their response to treatment. is pilot study shows that the structure and flow of NVs respond differently to treatment and can be quantitatively analyzed, followed by repeated optical coherence tomography angiography (OCTA)
We demonstrate different treatment responses after anti-Vascular endothelial growth factor DME (VEGF) between structural and angiographic NV for both area and flow density. e structure remained stable with regression of flow density, while NV-angio regressed with more constant flow density
Summary
Diabetic retinopathy (DR) is a leading cause of vision loss and blindness worldwide and presumably on the rise with expected demographics [1, 2]. Prospective clinical trials showed noninferior visual acuity (VA) results of intravitreal anti-VEGF (CLARITY for aflibercept; Protocol S for ranibizumab) compared to PRP [7, 9]. E CLARITY trial even showed improved VA, better treatment satisfaction scores, lower incidence of center-involving macular edema and vitreous hemorrhage, and less visual field loss with aflibercept than PRP [7]. Five-year data of Protocol S recently reported sustained noninferior VA outcomes and lower incidence of macular edema in the ranibizumab group [8]. Both of these studies have made treatment decisions about
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
